Y-mAbs Receives Breakthrough Therapy Designation for Naxitamab for the treatment of High Risk Neuroblastoma 21 August 2018
The FDA has granted Y-mAbs Breakthrough Therapy designation for naxitamab, in combination with GM-CSF,... Read more
The FDA has granted Y-mAbs Breakthrough Therapy designation for naxitamab, in combination with GM-CSF,... Read more
Biotech and Money is an influential community of senior life science decision makers conducting impactful... Read more
Og denne mail er sikkert blot én i rækken af en endeløs mailstrøm, hvor du skal læse og tage stilling... Read more
Seventh Program to enter Clinical Development at Symphogen Symphogen’s antibody platform is now validated... Read more
DANSK BIOTEK afholdt i år ordinær generalforsamling den 9. maj hos Novo i forbindelse med Årsmødet.... Read more
Den 9. maj 2018 kl. 13.30 hos NOVO, Tuborg Havnevej 19, 2900 Hellerup Dagsorden c.f. vedtægterne: a. ... Read more
For et par uger siden præsenterede regeringen sin længe ventede Vækstplan for life science. I DANSK... Read more
Appoints Internationally Renowned Scientific Advisors COPENHAGEN, Denmark— 8 February 2018: Acesion... Read more
COPENHAGEN, Denmark (November 30, 2017) – Symphogen, a private clinical late-stage antibody oncology-focused... Read more